Market Currents
More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of...
-
Tuesday, July 24, 2012, 12:36 PM ETMore on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of multiple-sclerosis treatment Avonex and cancer drug Rituxan, and reflecting a $50M charge last year. Ups FY EPS guidance to $6.20 from $6.15 prior, vs. consensus of 6.22. Shares flat at $139.28, although they had been as high as $142.68. BIIB had gained 27% YTD through yesterday.
Other date
Latest Earnings Articles
